🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Preventive Use of PIPAC in Locally Advanced Gastric Cancer.

RecruitingNAAges 18 Years - anyAllNational Research Oncology and Transplantology Ce…
NCT06784765 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related mortality. In patients with locally advanced gastric cancer, multimodal treatment strategies, including perioperative chemotherapy, have significantly improved survival rates. Despite these advances, peritoneal carcinomatosis (PC) remains a serious problem, occurring in 60% of cases after radical surgery. PC is associated with poor prognosis and limited treatment options. Intra-abdominal chemotherapy, particularly hyperthermic intraperitoneal chemoperfusion (HIPEC), has demonstrated advantages in the treatment of PC. However, a new technique, pressurized intraperitoneal aerosolized chemotherapy (PIPAC), is emerging as a promising alternative. PIPAC delivers chemotherapeutic agents directly to the peritoneal surface as an aerosol, allowing deeper penetration of drugs into tumor implants

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Adults aged 18-70 years with histologically confirmed locally advanced gastric adenocarcinoma (T3-4N0-3M0), ECOG performance status 0-2, and negative peritoneal cytology. Inclusion Criteria: 1. Signed informed consent 2. Aged 18-70 years 3. ECOG performance status 0-2 4. Histologically confirmed adenocarcinoma of the stomach (T3-4N0-3M0) 5. Negative peritoneal cytology from diagnostic laparoscopy 6. No prior chemotherapy or radiotherapy Exclusion Criteria: 1. Presence of distant metastases 2. Positive peritoneal cytology 3. Previous cancer treatment (chemotherapy, radiotherapy, or surgery) 4. Severe comorbid conditions contraindicating surgery or chemotherapy 5. Pregnancy or lactation 6. Known hypersensitivity to study drugs
💊

What it tests

  • Intervention Group
  • Control Group
📍

Where

1 site
National Research Oncology Centre
Astana, Kazakhstan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy